E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Non-Squamous cell Non-small cell lung cancer |
Carcinoma polmonare non-squamoso non a piccole cellule (NSCLC) |
|
E.1.1.1 | Medical condition in easily understood language |
Non-Squamous cell Non-small cell lung cancer |
Carcinoma Polmonare non-squamoso non a piccole cellule (NSCLC) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10029104 |
E.1.2 | Term | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The purpose of the study is to compare the overall survival of BMS- 936558 as compared with Docetaxel in subjects with non- squamous cell non-small cell lung cancer (NSCLC) after failure of prior platinumbased chemotherapy |
L'obiettivo principale dello studio è confrontare la sopravvivenza complessiva indotta da BMS-936558 rispetto a Docetaxel in soggetti con carcinoma polmonare non-squamoso non a piccole cellule che hanno fallito una precedente chemioterapia contenente platino |
|
E.2.2 | Secondary objectives of the trial |
1. To compare the objective response rate of BMS-936558 versus docetaxel 2. To compare the progression-free survival (PFS) of BMS-936558 versus docetaxel 3. To evaluate clinical benefit of BMS-936558 versus docetaxel, in PD-L1 + versus PD-L1- protein expression subgroups 4. To evaluate the proportion of subjects exhibiting disease-related symptom progression, as measured by LCSS, in BMS-936558 and docetaxel groups |
1. Confrontare la percentuale di risposta obiettiva indotta da BMS-936558 rispetto a Docetaxel 2. Confrontare la sopravvivenza libera da progressione (PFS) indotta da BMS-936558 rispetto a Docetaxel 3. Valutare il beneficio clinico indotto da BMS-936558 rispetto a Docetaxel nel sottogruppo di soggetti positivi all'espressione della proteina PD-L1 rispetto a quelli che non esprimono la proteina PD-L1 4. Valutare la percentuale di soggetti che mostrano sintomi di progressione correlati alla malattia, misurati attraverso la specifica scala di valutazione LCSS, nei due bracci BMS-936558 e Docetaxel |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Men & women >= 18 years of age 2) Subjects with histologically or cytologically-documented nonsquamous cell NSCLC who present with Stage IIIB/IV disease or recurrent disease following radiation therapy or surgical resection. 3)Disease recurrence or progression during/after one prior platinumcontaining chemotherapy regimen for advanced or metastatic disease 4) Measurable disease by CT/MRI per RECIST 1.1 criteria 5) ECOG performance status <= 1 6) An FFPE tumor tissue block or unstained slides of tumor sample (archival or recent) must be available for biomarker evaluation. Specimens must be received by the central lab prior to randomization. Biopsy should be excisional, incisional or core needle. Fine needle aspiration is insufficient |
1. Uomini e donne di età maggiore o uguale a 18 anni 2. Soggetti con carcinoma polmonare non-squamoso non a piccole cellule (NSCLC), documentato in termini istologici o citologici, con malattia allo stadio IIIB/IV o recidivante dopo radioterapia o rimozione chirurgica 3. Malattia recidivante o che è andata in progressione durante o dopo un precedente regime di chemioterapia contenente platino 4. Malattia misurabile tramite TAC/RMN sulla base dei criteri RECIST 1.1 5. Performance Status inferiore o uguale a 1 (ECOG) 6. Blocchetto di tessuto tumorale fissato in formalina e incluso in paraffina o vetrini non colorati contenenti sezioni di tessuto (di archivio o recenti) devono essere disponibili per l'analisi dei biomarker. Tali campioni devono pervenire al laboratorio centralizzato prima della randomizzazione. Il tessuto deve provenire da una biopsia escissionale, incisionale o ago aspirato profondo. L'ago aspirato sottile non è sufficiente. |
|
E.4 | Principal exclusion criteria |
1) Subjects with active CNS metastases are excluded. Subjects are eligible if CNS metastases are asymptomatic or adequately treated and subjects are neurologically returned to baseline for at least 2 weeks prior to enrollment. In addition, subjects must be either off corticosteroids, or on a stable or decreasing dose of <= 10mg daily prednisone (or equivalent) 2) Subjects with carcinomatous meningitis. 3) Subjects with active, known or suspected autoimmune disease, or subjects with interstitial lung disease. 4) Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of randomization. 5) Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways). 6) Prior treatment with docetaxel 7) Treatment with any investigational agent within 28 days of first administration of study treatment. |
1. Soggetti con metastatasi attive del sistema nervoso centrale sono esclusi. Tali soggetti possono essere inclusi se le metastasi sono adeguatamente trattate e i soggetti sono rientrati nel basale neurologico da almeno 2 settimane prima dell'arruolamento. Inoltre tali soggetti devono essere fuori dal trattamento con corticosteroidi o in dose stabile o decrescente inferiore o uguale a 10 mg di prednisone (o equivalenti). 2. Soggetti con meningite carcinomatosa 3. Soggetti con malattia autoimmune attiva, nota o sospetta, o soggetti con malattia polmonare interstiziale 4. Soggetti con una condizione clinica che richieda trattamento sistemico sia con corticosteroidi o altri farmaci immunosoppressivi nell'arco dei 14 giorni precedenti alla randomizzazione 5. Precedente trattamento con terapia anti-PD-1, anti-PD-L1, anti-PD.L2, anti-CD137, o anticorpo anti-CTLA-4 (incluso ipilimumab o qualunque altro anticorpo o farmaco che abbia come target specifico la costimolazione delle cellule T) 6. Precedente trattamento con Docetaxel 7. Trattamento con altri farmaci sperimentati nell'arco dei 28 giorni precedenti l'inizio della terapia con il farmaco in studio |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Overall Survival |
Sopravvivenza Complessiva (OS) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1. To compare the objective response rate of BMS-936558 versus docetaxel 2. To compare the progression-free survival (PFS) of BMS-936558 versus docetaxel 3. To evaluate clinical benefit of BMS-936558 versus docetaxel, in PD-L1 + versus PD-L1- protein expression subgroups 4. To evaluate the proportion of subjects exhibiting disease-related symptom progression, as measured by LCSS, in BMS-936558 and docetaxel groups |
1. Confrontare la percentuale di risposta obiettiva indotta da BMS-936558 rispetto a Docetaxel 2. Confrontare la sopravvivenza libera da progressione (PFS) indotta da BMS-936558 rispetto a Docetaxel 3. Valutare il beneficio clinico indotto da BMS-936558 rispetto a Docetaxel nel sottogruppo di soggetti positivi all’espressione della proteina PD-L1 rispetto a quelli che non esprimono la proteina PD-L1 4. Valutare la percentuale di soggetti che mostrano sintomi di progressione correlati alla malattia, misurati attraverso la specifica scala di valutazione LCSS, nei due bracci BMS-936558 e Docetaxel |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Assessments on: Biomarker, Outcomes Research(LCSS&EQ-5D), Immunogenicity |
Analisi su: Biomarkes, Indicatori di Esito(LCSS&EQ-5D), Immunogenicità |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 9 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 47 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Australia |
Brazil |
Canada |
Chile |
Hong Kong |
Mexico |
Peru |
Russian Federation |
Singapore |
South Africa |
Turkey |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study will end when analysis of survival is complete. All subjects will be followed for overall survival every 3 months until death, lost to follow-up or withdrawal of study consent. The duration of the study will be approximately 2 years (24 months). |
Lo studio si concluderà dopo completamento dell'analisi della sopravvivenza.Tutti i soggetti saranno seguiti per la sopravvivenza complessiva ogni 3 mesi fino a decesso, perdita al follow up,ritiro del consenso. Durata dello studio: circa 2 anni |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |